Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.
Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.
复制标题
纳曲酮/安非他酮治疗暴食症：一项随机、双盲、安慰剂对照试验。
DOI：
10.1002/oby.23898
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
McKee,SherryA
中科院分区：
文献类型：
--
作者：
Grilo,CarlosM;Lydecker,JanetA;Jastreboff,AniaM;Pittman,Brian;McKee,SherryA
暴食症（BED）是一种与肥胖相关的流行性精神疾病。对于BED，几乎没有基于证据的治疗方法，特别是药物治疗。本研究测试的疗效纳洛酮/安非他酮BED.MethodsA随机，双盲，安慰剂对照，12周的试验测试纳洛酮/安非他酮BED与不肥胖。89名患者（70.8%女性，69.7%白色，平均年龄45.7岁，平均BMI 35.1 kg/m2，77.5% BMI ≥ 30 kg/m2）被随机分配至安慰剂组（n= 46）或纳洛酮/安非他酮组（n= 43），随机化按肥胖状态和性别分层; 92.1%完成治疗后评估。结果暴饮暴食频率的混合模型显示，纳洛酮/安非他酮和安慰剂之间没有显着差异显着减少。暴食缓解率的Logistic回归显示，纳洛酮/安非他酮和安慰剂没有显著差异。肥胖状态不能预测或中度预测连续或分类考虑的暴饮暴食结局。混合模型显示，与安慰剂相比，纳洛酮/安非他酮与显著更大的体重减轻百分比相关。Logistic回归显示，纳洛酮/安非他酮组体重减轻≥5%的发生率显著高于安慰剂组（27.9% vs. 6.5%）。肥胖状态并没有预测或中度体重减轻outcomes. ConclusionsNaldrone/安非他酮并没有表现出有效性，减少暴饮暴食相对于安慰剂，但显示出有效性与床的患者体重减轻。肥胖状态不能预测或调节药物治疗结果。
ObjectiveBinge‐eating disorder (BED) is a prevalent psychiatric disorder associated with obesity. Few evidence‐based treatments exist for BED, particularly pharmacological options. This study tested the efficacy of naltrexone/bupropion for BED.MethodsA randomized, double‐blind, placebo‐controlled, 12‐week trial tested naltrexone/bupropion for BED with and without obesity. Eighty‐nine patients (70.8% women, 69.7% White, mean age 45.7 y, mean BMI 35.1 kg/m2, 77.5% with BMI ≥ 30 kg/m2) were randomized to placebo (n= 46) or naltrexone/bupropion (n= 43), with randomization stratified by obesity status and gender; 92.1% completed post‐treatment assessments.ResultsMixed models of binge‐eating frequency revealed significant reductions that did not differ significantly between naltrexone/bupropion and placebo. Logistic regression of binge‐eating remission rates revealed that naltrexone/bupropion and placebo did not differ significantly. Obesity status did not predict, or moderate, binge‐eating outcomes considered either continuously or categorically. Mixed models revealed that naltrexone/bupropion was associated with significantly greater percentage weight loss than placebo. Logistic regression revealed that naltrexone/bupropion had significantly higher rates of attaining ≥5% weight loss than placebo (27.9% vs. 6.5%). Obesity status did not predict or moderate weight‐loss outcomes.ConclusionsNaltrexone/bupropion did not demonstrate effectiveness for reducing binge eating relative to placebo but showed effectiveness for weight reduction in patients with BED. Obesity status did not predict or moderate medication outcomes.